Dr. Gitlitz on EGFR Exon 20 Insertion Mutations in Lung Cancer

Barbara J. Gitlitz, MD,

a

ssociate

p

rofessor of Clinical Medicine, Keck Hospital of USC Norris Comprehensive Cancer Center, discusses treating patients with

EGFR

exon 20 insertion mutations in lung cancer.

Exon 20 insertion mutations are the third most common type of

EGFR

mutation that

patients with

lung cancer present with, says Gitlitz. While this mutation will show up in a report as an

EGFR

mutation, it does not respond to any currently available EGFR inhibitors. It is important to be aware that a patient with an

EGFR

mutation has an

e

xon 20 insertion, explains Gitlitz.

Exon 20 insertion mutations are currently a target without a treatment, says Gitlitz. More clinical trials are needed.